AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Castle Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference

March 29, 2021 GMT

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Mar 29, 2021--

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 4:30 p.m. Eastern time.

A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/news-events/events-presentations. A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

ADVERTISEMENT

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx ® -Melanoma, DecisionDx ® -CM Seq), cutaneous squamous cell carcinoma (DecisionDx ® -SCC), suspicious pigmented lesions (DecisionDx ® DiffDx™-Melanoma) and uveal melanoma (DecisionDx ® -UM, DecisionDx ® -PRAME and DecisionDx ® -UM Seq ). For more information about Castle’s gene expression profile tests, visit www.CastleTestInfo.com. Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit www.CastleBiosciences.com.

ADVERTISEMENT

DecisionDx-Melanoma, DecisionDx-CM Seq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210329005745/en/

CONTACT: Investor and Media Contact:

Camilla Zuckero

832-835-5158

czuckero@castlebiosciences.com

KEYWORD: UNITED STATES NORTH AMERICA TEXAS

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL ONCOLOGY

SOURCE: Castle Biosciences, Inc.

Copyright Business Wire 2021.

PUB: 03/29/2021 05:00 PM/DISC: 03/29/2021 05:01 PM

http://www.businesswire.com/news/home/20210329005745/en